Insider Cluster (3 insiders) ·Filed May 7, 2026
Insider cluster: 2 insiders, $3.1M total
Actionable Insight • Neutral
Insider sales are routine and immaterial. The strong Q1 results, plus $750M buyback authorization, support the stock. No action warranted.
Final — all horizons settled through T+60d
EXEL ▲ +15.04% at T+60d
NEUTRAL call ✓ call won +15.04% · α vs SPY +12.93% · entry $46.10 → $53.03
T+1d
+4.45%
call +4.45% · α +3.62%
$48.15
settled 5mo ago
T+5d
+11.26%
call +11.26% · α +9.76%
$51.29
settled 5mo ago
T+20d
+11.94%
call +11.94% · α +8.80%
$51.60
settled 4mo ago
T+60d
+15.04%
call +15.04% · α +12.93%
$53.03
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Two Exelixis directors sold a combined $3.12M in open-market transactions following a strong Q1 2026 earnings beat (revenue +10%, EPS +44% YoY). The CEO gifted shares with no cash value. Total sales represent only 0.027% of market cap, well below materiality thresholds.
Key Financial Metrics
Direction
selling
Total Value
$3.1M
Insiders
3
Key Facts
- Director George Poste sold 60,000 shares for $2.74M on May 7
- Director Mary Beckerle sold 7,712 shares for $374K on May 7
- CEO Michael Morrissey gifted 109,676 shares (no cash value) on May 6
- Q1 2026 earnings beat: GAAP EPS $0.79 vs $0.55 YoY, revenue $610.8M vs $555.4M
- Sales represent 0.027% of Exelixis's $11.6B market cap
Financial Impact
$3.12M in open-market sales, trivial relative to $11.6B market cap
insider holdings
Risk Factors
- Further insider selling above 0.5% of market cap would be more concerning
- Zanzalintinib pivotal data and FDA decision (December 2026) are key catalysts
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
58% bullish (26 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-EXEL-1778281456308 |
12 reports for EXEL
67% Hit rate best @ T+60▲ +21.97%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $56.12 $58.36 | ▼ −3.99% | ▼ −4.21% | $57.94 (−3.24%) |
Aug 10, 2026 7w ago | Press Release | $51.33 $53.10 | ▼ −3.44% | ▼ −3.85% | $57.94 (−12.88%) |
Jun 3, 2026 17w ago | Insider Cluster | $52.39 $53.50 | ▲ +2.12% | ▲ +4.68% | $57.94 (+10.60%) |
May 29, 2026 17w ago | 8-K | $50.20 $52.70 | ▲ +4.98% | ▲ +7.73% | $57.94 (+15.42%) |
May 28, 2026 18w ago | Insider Cluster | $50.32 $51.60 | ▲ +2.55% | ▲ +2.84% | $57.94 (+15.15%) |
May 28, 2026 18w ago | Insider Cluster | $50.32 $51.60 | ▲ +2.55% | ▲ +2.84% | $57.94 (+15.15%) |
May 28, 2026 18w ago | Insider Cluster | $50.32 $52.69 | ▲ +4.71% | ▲ +7.23% | $57.94 (+15.15%) |
May 22, 2026 18w ago | Insider Cluster | $49.94 $48.49 | ▼ −2.90% | ▼ −4.12% | $57.94 (+16.02%) |
May 19, 2026 19w ago | Insider Cluster | $49.89 $51.46 | ▲ +3.15% | ▲ +1.34% | $57.94 (+16.14%) |
May 7, 2026 21w ago | Insider Cluster | $46.10 $51.29 | ▲ +11.26% | ▲ +9.76% | $57.94 (+25.69%) |
Showing 10 of 12
US Market Status
Market Closed — Opens in 1h 31m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access